Blauvelt, A., Rich, P., Sofen, H., Lambert, J., Merola, J. F., Lebwohl, M., Scharnitz, T., Hoyt, K., Kisa, R. M. and Banerjee, S. (2022) “Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials”, SKIN The Journal of Cutaneous Medicine, 6(6), p. s49. doi: 10.25251/skin.6.supp.49.